Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease

Table 4 Change in variables in obese with NAFLD children treated with GH vs control group for 6 months

Variable	rhGH group (n = 22)	control group (n = 22)	p value
BMI SDS	2.28 ± 0.80	2.71 ± 0.61	0.049*
IGF-1(ng/ml)	582.45 ± 133.00	359.64 ± 129.00	< 0.001*
CRP(mg/L)	1.17 ± 0.76	2.26 ± 1.43	0.003*
ALT(U/L)	15.00(10.90,22.50)	28.00(21.00, 54.25)	0.001*#
AST(U/L)	20.00(17.00,24.00)	24.50(21.75, 38.00)	0.004*▲
GGT(U/L)	14.50(13.75,18.25)	28.50(21.00, 36.00)	< 0.001*#
TC(mmol/L)	4.15 ± 0.64	4.30 ± 0.94	0.538
HDL-C (mmol/L)	1.30(1.23, 1.70)	1.15(1.01, 1.23)	0.005*#
LDL-C (mmol/L)	2.19 ± 0.42	2.61 ± 0.66	0.016*
TG(mmol/L)	1.06(0.72, 1.36)	1.05(0.73, 1.55)	0.589#
UA(μmol/L)	420.45 ± 85.38	397.82 ± 84.25	0.381
Insulin(uIU/mL)	25.19(17.33,41.33)	20.74(15.95, 28.63)	0.151#
FBG(mmol/L)	5.50 ± 0.44	5.36 ± 0.52	0.328
HOMA-IR	6.27(4.15, 9.14)	5.28(3.55, 6.63)	0.115#
WBISI	2.82 ± 1.21	3.01 ± 1.25	0.613
HbA1c (%)	5.66 ± 0.20	5.64 ± 0.32	0.866

^# p value reported for log transformed values, but values in the table represent a back transformation to the original▲Mann–Whitney U test
^* p < 0.05
Abbreviations: BMI SDS body mass index standard deviation scores, IGF-1 Insulin-like growth factor 1, CRP C reactive protein, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT Gamma-glutamyl transferase, GH growth hormone, TC total cholesterol, HDL-C High density lipoprotein cholesterol, LDL-C Low density lipoprotein cholesterol, TG triglycerides, UA Uric acid, FBG fasting blood glucose, HOMA-IR homeostasis model assessment of IR, WBISI Whole body insulin sensitivity index, HbA1c Glycosylated haemoglobin

ISSN: 1472-6823